Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is an autoimmune disease in which the small bile ducts inside the liver are progressively destroyed. Bile backs up, liver enzymes rise, and over years the damage can advance to fibrosis and cirrhosis. Ursodeoxycholic acid (UDCA) has been the first-line prescription treatment for decades.
PBC is unusual among the topics covered on this site because it is the one condition where TUDCA, the taurine-conjugated form of UDCA, has been compared directly against standard-of-care UDCA in a randomized, double-blind, multicenter trial in humans. Most TUDCA research is cell-culture or animal work. This is not. That makes the evidence unusually informative, and it also makes the caveats unusually important, because PBC is a diagnosed liver disease managed by a hepatologist, not a self-treatment target. Nothing here is medical advice.
Key Takeaways
- A 199-patient multicenter, randomized, double-blind trial compared 250 mg TUDCA three times daily against 250 mg UDCA three times daily for 24 weeks in Chinese PBC patients [1].
- At week 24, 75.97% of the TUDCA group and 80.88% of the UDCA group hit the primary endpoint of a greater than 25% drop in alkaline phosphatase. The difference was not statistically significant (P = 0.453) [1].
- Itching (pruritus/scratch) rose from 1.43% to 10.00% in the UDCA group but did not change in the TUDCA group (P = 0.023) [1], the one endpoint where the two compounds diverged.
- An earlier dose-response study in 24 PBC patients tested 500, 1000, and 1500 mg daily for six months and concluded that roughly 10 mg/kg/day is the appropriate dose for long-term study [2].
- These trials used pharmaceutical-grade TUDCA at prescribed doses under specialist supervision. They are not evidence that an over-the-counter supplement can replace prescribed PBC therapy.
Why PBC Is the Best-Studied Human TUDCA Indication
UDCA works in PBC by enriching the bile acid pool with a hydrophilic, less cytotoxic bile acid, displacing the more detergent-like hydrophobic bile acids that accumulate when bile flow is obstructed. TUDCA is UDCA bonded to taurine, which makes it more water soluble still. The obvious research question follows directly: if hydrophilicity is part of what makes UDCA useful, does the more hydrophilic conjugate work better?
That question has been studied in PBC patients since the 1990s, which is why the human evidence base here is deeper than for any other TUDCA indication. Researchers in Italy ran dose-response and crossover studies, then a large Chinese multicenter group ran the definitive head-to-head trial two decades later.
The 2016 Head-to-Head Trial: TUDCA vs. UDCA
The most important study is a multicenter, randomized, double-blind trial published in 2016. It enrolled 199 PBC patients and assigned them either 250 mg TUDCA plus UDCA placebo, or 250 mg UDCA plus TUDCA placebo, three times per day for 24 weeks [1]. Double-dummy design, so neither patients nor investigators knew which bile acid a given person was receiving.
The primary endpoint was the percentage of patients achieving a reduction in serum alkaline phosphatase (ALP) of more than 25% from baseline. ALP is the standard biochemical marker of treatment response in PBC. At 24 weeks, 75.97% of the TUDCA group and 80.88% of the UDCA group met it (P = 0.453) [1]. A stricter threshold of greater than 40% ALP reduction was met by 55.81% on TUDCA and 52.94% on UDCA (P = 0.699) [1]. Aspartate aminotransferase and total bilirubin improved similarly in both arms.
In plain terms: TUDCA performed about as well as the standard of care on the biochemical markers that matter in PBC, and neither compound clearly beat the other. The authors concluded TUDCA is safe and as efficacious as UDCA for PBC.
The One Place the Two Compounds Differed: Itching
Cholestatic itching is one of the most miserable symptoms of PBC and one of the reasons patients stop treatment. In this trial, the proportion of patients reporting pruritus/scratch rose from 1.43% to 10.00% in the UDCA group over 24 weeks, while the TUDCA group showed no change (P = 0.023) [1]. The authors noted TUDCA may be better than UDCA at relieving symptoms.
This is a single secondary endpoint in a single trial, and symptom reporting is more subjective than a serum ALP measurement. It has not been replicated in an independent trial. It is worth knowing about and not worth treating as settled.
Dose: What the Earlier Studies Established
Before the head-to-head trial, an Italian group ran a dose-response study in 24 PBC patients randomly assigned to 500, 1000, or 1500 mg of TUDCA daily for six months [2]. Serum liver enzymes dropped significantly after the first month at all three doses, with no significant difference between them, though further reduction over time occurred at the two higher doses. Plasma total and HDL cholesterol fell significantly in the two higher-dose groups [2]. Diarrhea was the only reported side effect.
The authors concluded that approximately 10 mg/kg body weight per day is the appropriate dose for long-term studies [2]. For a 70 kg adult that is roughly 700 mg daily, which is in the same range as the 750 mg/day (250 mg three times daily) used in the 2016 trial.
A smaller crossover pilot study compared UDCA and TUDCA directly in PBC patients [3], and separate work characterized how orally administered TUDCA is metabolized and distributed in PBC patients specifically [4], confirming that the taurine conjugate does enrich the bile acid pool as intended rather than simply being deconjugated and behaving identically to UDCA.
What This Evidence Can and Cannot Tell Us
What it can tell us: in patients with diagnosed PBC, TUDCA at roughly 750 mg/day produces biochemical improvement comparable to the same dose of UDCA over 24 weeks, with a comparable adverse event profile and possibly less treatment-emergent itching.
What it cannot tell us: whether TUDCA changes long-term outcomes such as progression to cirrhosis, need for transplant, or survival. The trial ran 24 weeks and used a biochemical surrogate endpoint. PBC is measured in decades. UDCA earned first-line status partly on long-term outcome data that TUDCA does not have.
It also cannot tell us anything about over-the-counter TUDCA supplements as a PBC treatment. The trials used defined pharmaceutical preparations at prescribed doses with regular liver-panel monitoring. PBC that is undertreated or mistreated progresses. Anyone with diagnosed PBC should be managing it with a hepatologist, and any interest in TUDCA belongs in that conversation rather than in a supplement order.
Frequently Asked Questions
Is TUDCA better than UDCA for PBC?
On the primary biochemical endpoint, no. The 199-patient randomized trial found no statistically significant difference between TUDCA and UDCA in the proportion of patients achieving a greater than 25% ALP reduction at 24 weeks [1]. TUDCA showed an advantage on treatment-emergent itching in that same trial [1], which is a secondary finding awaiting replication.
What dose was used in the PBC trials?
The 2016 head-to-head trial used 250 mg three times daily, or 750 mg/day [1]. The earlier dose-response study concluded roughly 10 mg/kg/day is appropriate for long-term use [2]. These were supervised trial doses, not self-directed supplement regimens.
Can I take TUDCA instead of my prescribed UDCA?
That is a decision for your hepatologist, not a supplement decision. UDCA has long-term outcome data in PBC that TUDCA does not, treatment response in PBC is monitored with regular blood work, and switching therapy without that monitoring risks silent disease progression. Bring the trial data to your specialist rather than acting on it alone.
Does TUDCA help with PBC itching?
In the 2016 trial, itching increased in the UDCA arm over 24 weeks but not in the TUDCA arm [1]. That is one secondary endpoint from one trial. It is a reason to raise the question with a specialist, not a demonstrated antipruritic effect.
References
- A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore) (2016).
- Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Digestive Diseases and Sciences (1996).
- Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary Pharmacology & Therapeutics (1997).
- Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut (1996).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
